DJIA 18,077.28 -2.86 -0.02%
NASDAQ 5,075.60 -16.49 -0.32%
S&P 500 2,115.03 -2.66 -0.13%
market minute promo


2.34 -0.12 (-4.97%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $2.34 -4.97%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.46
Previous Close $2.46
Daily Range $2.31 - $2.46
52-Week Range $2.28 - $5.95
Market Cap $242.9M
P/E Ratio -3.08
Dividend (Yield) $0.00 (0.0%)
Volume 530,058
Average Daily Volume 2,287,827
Current FY EPS -$1.30




Drug Makers

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary Rss Feed

Arena Pharmaceuticals Inc.'s Plan to Win the Obesity Drug War

Building a better mousetrap.

Vivus-Qsymia Sales Continue To Stumble Along - Equity Does The Same

Orexigen: Contrave Sales Pop, Equity Response Muted

Orexigen Has Contrave Recapturing Early-Year Form, But Needs European Launch

10 Most Hated Companies in Healthcare

When emotional trading is on display, the short-sellers come out to play. Find out which companies are the most hated in healthcare, why they're so universally disliked, and which company may eventually deserve a reprieve.

Orexigen - Contrave Sales Outpace Competition, But Are Still Not Enough

What Novo Nordisk's Entry Into The Obesity Space Means To The Sector

Orexigen Faces Generic Challenge For Anti-Obesity Drug

VIVUS Responds to Teva's Filing for Qsymia Generics - Analyst Blog

3 Promising Healthcare Stocks Under $10

Healthcare stocks with plenty of potential -- and low share prices

See More VVUS News...

VVUS's Top Competitors

VVUS $2.34 (-4.97%)
Current stock: VVUS
JNJ $100.77 (-0.31%)
Current stock: JNJ
NVS $104.84 (0.54%)
Current stock: NVS
RHHBY $36.55 (0.86%)
Current stock: RHHBY